HER2 or not HER2: That is the question

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3656-3659

  Burstein, Harold J ^a   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DISEASE CLASSIFICATION; EDITORIAL; HORMONAL THERAPY; HUMAN; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; METABOLISM; NOTE; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; REMISSION INDUCTION;

EID: 20544455368     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.910     Document Type: Editorial

References (28)

1. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
2. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
3. Wang ZC, Lin M, Wei LJ, et al: Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64-71, 2004
4. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:10.1200/JCO.2005.07.032
5. Schwartz GF, Hortobagyi GN: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100:2512-2532, 2004
6. Burstein HJ, Harris LN, Gelman R, et al: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53, 2003
7. Harris L, Burstein HJ, Gelman R, et al: Preoperative trastuzumab and vinorelbine is a highly active, well tolerated regimen for HER2 3+/FISH + stage II/III breast cancer. Proc Am Soc Clin Oncol 22:22, 2003 (abstr 86)
8. Slamon DJ, Clark GM, Wong WG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
9. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604-1608, 1985
10. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15, 2001
11. Schiff R, Massarweh S, Shou J, et al: Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9:447S-454S, 2003 (suppl 1)
12. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003
13. Albain K, Green S, Ravdin P, et al: Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc Am Soc Clin Oncol 20:24a, 2001 (abstr 94)
14. Albain K, Barlow W, O'Malley F, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III Intergroup trial 0100 (SWOG-8814). Proceedings of the 27th San Antonio Breast Cancer Symposium, 2004. Available at: http://www.abstracts2view.com/ sabcs/
15. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001
16. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11:647-663, 2000
17. Henderson IC, Berry DA, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
18. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
19. Venturini M, Aitini E, Del Mastro L, et al: Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients: Results from GONO-MIG1 study. Breast Cancer Res Treat 82:S9, 2003 (suppl 1, abstr 12)
20. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combina with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
21. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
22. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
23. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
24. Smith IE, Dowsett MD: Comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 82:S6, 2003 (suppl 1, abstr 1)
25. Pritchard KI: Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: Will it play in Peoria? J Clin Oncol 19:3795-3797, 2001
26. Stal O, Borg A, Ferno M, et al: ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11:1545-1550, 2000
27. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 88:S15, 2004 (suppl 1, abstr 24)
28. Valagussa P: HER2 status: A statistician's view. Ann Oncol 12:S29-S34, 2001 (suppl 1)